Dr. Hua is a seasoned drug developer who has 20 years’ global clinical development and new drug registration experience with track records. Prior to founding BioNova, Dr. Hua was Senior VP, Head of Clinical Development and Regulatory Affairs at Hutchison MediPharma where he built up a development organization of 80+ employees across seven line functions with sites in Shanghai, Beijing, Guangzhou, Melbourne Australia and New Jersey USA. During his tenure at Hutchison MediPharma, Dr. Hua rapidly expanded development pipeline from five small molecules seven Phase 1 trials to eight small molecules for which half assets advanced to pivotal/registration trials. Dr. Hua led fruquintinib NDA submission in mCRC indication via MAH pilot policy in China and received regulatory approval. Native from Shanghai, Dr. Hua graduated from Fudan University Shanghai Medical College in 1992. He spent 16 years in the US in the field of clinical development with most significant achievements being regulatory submission and approval of Humira, Reclast/Aclasta, Zometa, Revlimid and Pomalyst.
Dr. Huang brings more than 20 years’ experience in medical research, pharmaceutic drug development and healthcare investment banking. Prior to co-founding BioNova, Dr. Huang was the Head of Business Development and Strategy at Immunomedics, responsible for all collaborations, licensing and acquisitions as well as development and portfolio strategy. Dr. Huang was previously BD and Portfolio Strategy Lead at Celgene for hematology and oncology franchise. He also worked as biotech equity analyst before joining pharmaceutical industry, covering 50+ companies across a variety of therapeutic areas with enstensive experience in primary and secondary stock underwriting and BD transactions totaled more than $20B.
Dr. Huang has 20 years’ experience in the field of drug discovery and development, covering disease areas from oncology, CNS, immunology, to cardiovescular and metabolic disorders. Worked for global pharmaceutical companies in the US, Dr. Huang led or contributed to more than 10 new drugs discovery and development. In 2012, Dr. Huang returned to Shanghai and became the leader of small molecule discovery at Novartis Institute of Biomedical Research (NIBR) where she successfully led an epigenetic discovery project and delivered to the next development stage.
Dr. Huang graduated from Shanghai Jiao Tong University (PhD), and Shanghai Institute of Pharmaceutical Industry (MS), and joined BioNova with more than 15 years’ experience in the pharmaceutical industry. Dr. Huang was former Deputy General Manager of R&D at Sinopharm Shanghai Shyndec Pharmaceutical, and former Head of Regulatory Affairs at Aurobindo Pharma Limited (China). He specializes in regulatory affairs for domestic and imported new drug registration and marketing authorization.
Winnie joined BioNova as Head of Operation in 2019. Prior to joining BioNova, Winnie was HR & Admin manager at Pivotal Bioventure Partners where she was responsible for company payroll, employee benefits, talent acquisition, government affairs, and general administration. Earlier in her career, Winnie worked in the HR field at I-Bridge Capital and Hutchsion MediPharma. Winnie received a Bachelor Degree in Business Administration from Shanghai Normal University.
Yu graduated from Tongji Medical College, Huazhong University of Science and Technology. She specialized in hematology and worked as resident and attending physician for 8 years prior to joining the pharmaceutical industry. As a physician scientist, Yu devoted in clinical development for target therapies and CAR-T cell therapy for hematologic malignancies, and successfully led the clinical development program and the regulatory filing of the first CAR-T cell therapy in China.